Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Purinostat mesylate injection combination therapy in advanced solid tumors
CTR20241672Phase 2Active
- Sponsor
- Zeling Biopharma
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of purinostat in Nonhematologic neoplasms (3 arms), sponsored by Zeling Biopharma. Primary endpoint: Objective response rate. Started May 2024; status: active.
02
Drugs
purinostat
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20241672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241672.